New class of weight-loss drugs may offer an alternative to GLP-1s: 5 things to know
obesity, with a phase 2 trial finding that the amylin analogue petrelintide reduced body weight by up to 10.7% through week 42, according to a study published Sept. 29 in The Lancet Diabetes & Endocrinology. Here are five things to know: The post New class of weight-loss drugs may offer an alternative to GLP-1s: 5 things to know appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.